As of 2026-05-22, the EV/EBITDA ratio of WuXi Biologics (Cayman) Inc (2269.HK) is 19.46. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 2269.HK's latest enterprise value is 130,104.05 mil HKD. 2269.HK's TTM EBITDA according to its financial statements is 6,687.03 mil HKD. Dividing these 2 quantities gives us the above 2269.HK EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 15.3x - 19.7x | 17.4x |
| Forward P/E multiples | 9.0x - 12.2x | 9.2x |
| Fair Price | 30.19 - 44.77 | 34.12 |
| Upside | -8.9% - 35.1% | 2.9% |
| Date | EV/EBITDA |
| 2026-05-20 | 138.79 |
| 2026-05-19 | 138.20 |
| 2026-05-18 | 137.95 |
| 2026-05-15 | 141.07 |
| 2026-05-14 | 136.68 |
| 2026-05-13 | 141.83 |
| 2026-05-12 | 141.15 |
| 2026-05-11 | 138.45 |
| 2026-05-08 | 136.77 |
| 2026-05-07 | 139.38 |
| 2026-05-06 | 138.12 |
| 2026-05-05 | 141.74 |
| 2026-05-04 | 144.78 |
| 2026-04-30 | 138.37 |
| 2026-04-29 | 142.16 |
| 2026-04-28 | 141.15 |
| 2026-04-27 | 139.38 |
| 2026-04-24 | 140.39 |
| 2026-04-23 | 142.08 |
| 2026-04-22 | 146.72 |
| 2026-04-21 | 147.90 |
| 2026-04-20 | 149.08 |
| 2026-04-17 | 149.67 |
| 2026-04-16 | 155.82 |
| 2026-04-15 | 155.06 |
| 2026-04-14 | 155.99 |
| 2026-04-13 | 147.81 |
| 2026-04-10 | 150.43 |
| 2026-04-09 | 148.91 |
| 2026-04-08 | 147.39 |
| 2026-04-02 | 146.55 |
| 2026-04-01 | 146.04 |
| 2026-03-31 | 138.29 |
| 2026-03-30 | 131.29 |
| 2026-03-27 | 135.50 |
| 2026-03-26 | 132.05 |
| 2026-03-25 | 138.79 |
| 2026-03-24 | 141.91 |
| 2026-03-23 | 135.67 |
| 2026-03-20 | 141.66 |
| 2026-03-19 | 142.92 |
| 2026-03-18 | 148.83 |
| 2026-03-17 | 146.38 |
| 2026-03-16 | 146.04 |
| 2026-03-13 | 144.61 |
| 2026-03-12 | 147.14 |
| 2026-03-11 | 151.27 |
| 2026-03-10 | 153.46 |
| 2026-03-09 | 148.40 |
| 2026-03-06 | 152.28 |